Microevolution of the pathogenic yeasts Candida albicans and Candida glabrata during antifungal therapy and host infection
Open accessThe DOI matches its Crossref record; 85 of the 85 references it cites were found in a registry or an index.
Abstract
Microevolution of the pathogenic yeasts Candida albicans and Candida glabrata during antifungal therapy and host infection – Infections by the pathogenic yeasts Candida albicans and Candida glabrata are among the most common fungal diseases. The success of these species as human pathogens is contingent on their ability to resist antifungal therapy and thrive within the human host. C. glabrata is especially resilient to azole antifungal treatment, while C. albicans is best known for its wide array of virulence features. The core mechanisms that underlie antifungal resistance and virulence in these pathogens has been continuously addressed, but the investigation on how such mechanisms evolve according to each environment is scarcer. This review aims to explore current knowledge on microevolution experiments to several treatment and host-associated conditions in C. albicans and C. glabrata (...)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonfilamentous C. albicans Mutants Are Avirulent
Lo, H.-J., Köhler, J. R., DiDomenico, B., Loebenberg, D., Cacciapuoti, A., & Fink, G. R. (1997) · Cell · doi:10.1016/s0092-8674(00)80358-x · Cited by 1,809
Nosocomial Bloodstream Infections in United States Hospitals: A Three‐Year Analysis
Edmond, M. B., Wallace, S. E., McClish, D. K., Pfaller, M. A., Jones, R. N., & Wenzel, R. P. (1999) · Clinical Infectious Diseases · doi:10.1086/520192 · Cited by 1,387
Evolution Experiments with Microorganisms: The Dynamics and Genetic Bases of Adaptation
Elena, S. F., & Lenski, R. E. (2003) · Nature Reviews Genetics · doi:10.1038/nrg1088 · Cited by 1,386 · cited 2×
“Genetic adaptation is especially rapid when microbial populations are introduced into new environments [77].”
BackgroundCornely, O. A., Bassetti, M., Calandra, T., Garbino, J., Kullberg, B. J., Lortholary, O., Meersseman, W., Akova, M., Arendrup, M. C., Arikan-Akdagli, S., et al. (2012) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12039 · Cited by 1,217
Denning, D. W. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14472-8 · Cited by 1,131 · cited 1×
“These antifungals target the fungal cell-wall by acting as noncompetitive inhibitors of β-(1,3)-D-glucan synthase enzyme complex which catalyzes the production of glucan, the major component in Candida cell walls [26, 54].”
BackgroundGrowth of Candida albicans hyphae
Sudbery, P. E. (2011) · Nature Reviews Microbiology · doi:10.1038/nrmicro2636 · Cited by 1,110
Epidemiology of Invasive Mycoses in North America
Pfaller, M. A., & Diekema, D. J. (2010) · Critical Reviews in Microbiology · doi:10.3109/10408410903241444 · Cited by 901
Aneuploidy and Isochromosome Formation in Drug-Resistant Candida albicans
Selmecki, A., Forche, A., & Berman, J. (2006) · Science · doi:10.1126/science.1128242 · Cited by 733
A Recently Evolved Transcriptional Network Controls Biofilm Development in Candida albicans
Nobile, C. J., Fox, E. P., Nett, J. E., Sorrells, T. R., Mitrovich, Q. M., Hernday, A. D., Tuch, B. B., Andes, D. R., & Johnson, A. D. (2012) · Cell · doi:10.1016/j.cell.2011.10.048 · Cited by 711
Hsp90 Potentiates the Rapid Evolution of New Traits: Drug Resistance in Diverse Fungi
Cowen, L. E., & Lindquist, S. (2005) · Science · doi:10.1126/science.1118370 · Cited by 698 · cited 1×
“albicans isolates to evaluate the impact of the essential chaperone Hsp90 in the natural evolutionary process [96].”
BackgroundCandida Biofilms: Threats, Challenges, and Promising Strategies
Cavalheiro, M., & Teixeira, M. C. (2018) · Frontiers in Medicine · doi:10.3389/fmed.2018.00028 · Cited by 690 · cited 2×
“albicans in several in vitro studies [109, 112].”
BackgroundSelf-citationDevelopment and regulation of single- and multi-species Candida albicans biofilms
Lohse, M. B., Gulati, M., Johnson, A. D., & Nobile, C. J. (2018) · Nature Reviews Microbiology · doi:10.1038/nrmicro.2017.107 · Cited by 643
White, T. C. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.7.1482 · Cited by 612
Amphotericin primarily kills yeast by simply binding ergosterol
Gray, K. C., Palacios, D. S., Dailey, I., Endo, M. M., Uno, B. E., Wilcock, B. C., & Burke, M. D. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1117280109 · Cited by 608 · cited 1×
“tionally, merely the binding of AmB to ergosterol was shown to kill yeast cells, with pore formation being a complementary mechanism [66].”
BackgroundRegulatory circuitry governing fungal development, drug resistance, and disease.
Shapiro, R. S., Robbins, N., & Cowen, L. E. (2011) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00045-10 · Cited by 576
Mukherjee, P. K., Chandra, J., Kuhn, D. M., & Ghannoum, M. A. (2003) · Infection and Immunity · doi:10.1128/iai.71.8.4333-4340.2003 · Cited by 511 · cited 1×
“Still, these antifungals are inactive against biofilm-associated infections, which is a significant public health problem due to the increasing usage of medical devices [28].”
BackgroundPark, S., Kelly, R., Kahn, J. N., Robles, J., Hsu, M.-J., Register, E., Li, W., Vyas, V., Fan, H., Abruzzo, G., et al. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.8.3264-3273.2005 · Cited by 434
An insight into the antifungal pipeline: selected new molecules and beyond
Ostrosky-Zeichner, L., Casadevall, A., Galgiani, J. N., Odds, F. C., & Rex, J. H. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3074 · Cited by 432
Cowen, L. E., Singh, S. D., Köhler, J. R., Collins, C., Zaas, A. K., Schell, W. A., Aziz, H., Mylonakis, E., Perfect, J. R., Whitesell, L., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0813394106 · Cited by 413
Putative Role of β-1,3 Glucans in Candida albicans Biofilm Resistance
Nett, J., Lincoln, L., Marchillo, K., Massey, R., Holoyda, K., Hoff, B., VanHandel, M., & Andes, D. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01056-06 · Cited by 407 · cited 1×
“Although very simply described herein, the formation of Candida biofilms is a very complex process which relies on different mechanisms, such as cell-tocell adhesion, crucial for the integrity of the biofilm [113], or the formation of the ECM, composed by different EPS, some identified as important for the resistance…”
BackgroundAntifungal drug resistance among Candida species: mechanisms and clinical impact
Sanguinetti, M., Posteraro, B., & Lass‐Flörl, C. (2015) · Mycoses · doi:10.1111/myc.12330 · Cited by 394
Puig, S., Askeland, E., & Thiele, D. J. (2005) · Cell · doi:10.1016/j.cell.2004.11.032 · Cited by 382 · cited 1×
“cerevisiae, CTH2 is known for its role in the post-transcriptional regulation of iron limitation response through degradation of mRNAs encoding proteins involved in iron-dependent processes [143, 144].”
BackgroundEvolution of antifungal-drug resistance: mechanisms and pathogen fitness
Anderson, J. B. (2005) · Nature Reviews Microbiology · doi:10.1038/nrmicro1179 · Cited by 375
Candida albicans dimorphism as a therapeutic target
Jacobsen, I. D., Wilson, D., Wächtler, B., Brunke, S., Naglik, J. R., & Hube, B. (2012) · Expert Review of Anti-infective Therapy · doi:10.1586/eri.11.152 · Cited by 363
Hsp90 Governs Echinocandin Resistance in the Pathogenic Yeast Candida albicans via Calcineurin
Singh, S. D., Robbins, N., Zaas, A. K., Schell, W. A., Perfect, J. R., & Cowen, L. E. (2009) · PLoS Pathogens · doi:10.1371/journal.ppat.1000532 · Cited by 362
Morschhäuser, J., Barker, K. S., Liu, T. T., Blaß-Warmuth, J., Homayouni, R., & Rogers, P. D. (2007) · PLoS Pathogens · doi:10.1371/journal.ppat.0030164 · Cited by 355
The evolution of drug resistance in clinical isolates of Candida albicans.
Ford, C. B., Funt, J. M., Abbey, D., Issi, L., Guiducci, C., Martinez, D. A., Delorey, T., Li, B. Y., White, T. C., Cuomo, C., et al. (2015) · eLife · doi:10.7554/elife.00662 · Cited by 348
Franz, R., Kelly, S. L., Lamb, D. C., Kelly, D. E., Ruhnke, M., & Morschhäuser, J. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.12.3065 · Cited by 339 · cited 1×
“Consistent with previous reports addressing the acquisition of azole resistance [91, 98], the development of azole resistance in C.”
BackgroundSanglard, D., Ischer, F., Calabrese, D., Majcherczyk, P. A., & Bille, J. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.11.2753 · Cited by 337
An isochromosome confers drug resistance in vivo by amplification of two genes, ERG11 and TAC1
Selmecki, A., Gerami‐Nejad, M., Paulson, C., Forche, A., & Berman, J. (2008) · Molecular Microbiology · doi:10.1111/j.1365-2958.2008.06176.x · Cited by 325
Fitness Trade-offs Restrict the Evolution of Resistance to Amphotericin B
Vincent, B. M., Lancaster, A. K., Scherz-Shouval, R., Whitesell, L., & Lindquist, S. (2013) · PLoS Biology · doi:10.1371/journal.pbio.1001692 · Cited by 322 · cited 1×
“sequenced sequentially laboratory evolved strains and observed that mutations in ERG6 followed by loss of heterozygosity of chromosome 3, where ERG6 resides, were behind AmB resistance acquisition [84].”
BackgroundGenetic and phenotypic intra-species variation in Candida albicans
Hirakawa, M. P., Martinez, D. A., Sakthikumar, S., Anderson, M. Z., Berlin, A., Gujja, S., Zeng, Q., Zisson, E., Wang, J. M., Greenberg, J. M., et al. (2015) · Genome Research · doi:10.1101/gr.174623.114 · Cited by 320
Selmecki, A. M., Dulmage, K., Cowen, L. E., Anderson, J. B., & Berman, J. (2009) · PLoS Genetics · doi:10.1371/journal.pgen.1000705 · Cited by 319
Sanguinetti, M., Posteraro, B., Fiori, B., Ranno, S., Torelli, R., & Fadda, G. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.2.668-679.2005 · Cited by 319
Pande, K., Chen, C., & Noble, S. M. (2013) · Nature Genetics · doi:10.1038/ng.2710 · Cited by 306
Genotypic Evolution of Azole Resistance Mechanisms in Sequential Candida albicans Isolates
Coste, A., Selmecki, A., Forche, A., Diogo, D., Bougnoux, M.-E., d'Enfert, C., Berman, J., & Sanglard, D. (2007) · Eukaryotic Cell · doi:10.1128/ec.00151-07 · Cited by 305
Ferrari, S., Ischer, F., Calabrese, D., Posteraro, B., Sanguinetti, M., Fadda, G., Rohde, B., Bauser, C., Bader, O., & Sanglard, D. (2009) · PLoS Pathogens · doi:10.1371/journal.ppat.1000268 · Cited by 295 · cited 1×
“glabrata virulence [48], increased expression of adhesins and increased adherence to host epithelial cells [87, 102].”
BackgroundIn Vitro Activity of Caspofungin against Candida albicans Biofilms
Bachmann, S. P., VandeWalle, K., Ramage, G., Patterson, T. F., Wickes, B. L., Graybill, J. R., & López-Ribot, J. L. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.11.3591-3596.2002 · Cited by 288
Stress, drugs, and evolution: the role of cellular signaling in fungal drug resistance.
Cowen, L. E., & Steinbach, W. J. (2008) · Eukaryotic Cell · doi:10.1128/ec.00041-08 · Cited by 285 · cited 15×
“Both chromosome 3, which comprises CDR1 and CDR2 (efflux pumps coding genes) and MRR1 (MDR1 efflux pump regulator), and chromosome 5, which contains ERG11 and TAC1 (positive regulator of CDR1 and CDR2), were found to suffer LOH.”
BackgroundInfluentialVermitsky, J.-P., & Edlind, T. D. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.10.3773-3781.2004 · Cited by 285 · cited 1×
“glabrata, several studies suggest that mutations in ERG11 are not involved in clinical azole resistance in this pathogen [8, 41, 42].”
BackgroundKaur, R., Ma, B., & Cormack, B. P. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0611195104 · Cited by 284
Healey, K. R., Zhao, Y., Perez, W. B., Lockhart, S. R., Sobel, J. D., Farmakiotis, D., Kontoyiannis, D. P., Sanglard, D., Taj-Aldeen, S. J., Alexander, B. D., et al. (2016) · Nature Communications · doi:10.1038/ncomms11128 · Cited by 276 · cited 1×
“Interestingly, both isolates carried a nonsynonymous mutation in MSH2 known to favour the hyper-mutator phenotype (V239L) and the number of accumulated mutations between both clinical isolates was shown to be consistent with the presence of a MSH2 defect [101].”
BackgroundAntifungal Drugs: The Current Armamentarium and Development of New Agents
Robbins, N., Wright, G. D., & Cowen, L. E. (2016) · Microbiology Spectrum · doi:10.1128/microbiolspec.funk-0002-2016 · Cited by 271
Sanglard, D., Ischer, F., & Bille, J. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.4.1174-1183.2001 · Cited by 247
Flowers, S. A., Barker, K. S., Berkow, E. L., Toner, G., Chadwick, S. G., Gygax, S. E., Morschhäuser, J., & Rogers, P. D. (2012) · Eukaryotic Cell · doi:10.1128/ec.00215-12 · Cited by 239
Dunkel, N., Liu, T. T., Barker, K. S., Homayouni, R., Morschhäuser, J., & Rogers, P. D. (2008) · Eukaryotic Cell · doi:10.1128/ec.00103-08 · Cited by 236
Vermitsky, J., Earhart, K. D., Smith, W. L., Homayouni, R., Edlind, T. D., & Rogers, P. D. (2006) · Molecular Microbiology · doi:10.1111/j.1365-2958.2006.05235.x · Cited by 233
HSP90 inhibitors: current development and potential in cancer therapy
Sidera, K., & Patsavoudi, E. (2013) · Recent Patents on Anti-Cancer Drug Discovery · doi:10.2174/15748928113089990031 · Cited by 222 · cited 1×
“undergoing clinical evaluation [97] and present a good alternative to prevent de novo evolution of resistance.”
BackgroundSeider, K., Brunke, S., Schild, L., Jablonowski, N., Wilson, D., Majer, O., Barz, D., Haas, A., Kuchler, K., Schaller, M., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003730 · Cited by 220
Upregulation of ERG Genes in Candida Species by Azoles and Other Sterol Biosynthesis Inhibitors
Henry, K. W., Nickels, J. T., & Edlind, T. D. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.10.2693-2700.2000 · Cited by 216 · cited 1×
“Although this was observed in laboratorial experiments, through ERG11 upregulation [154, 155] or increased protein abundance [156], however, these mechanisms do not appear to play such a prominent role in clinical resistant”
BackgroundEvolution of Drug Resistance in Experimental Populations of Candida albicans
Cowen, L. E., Sanglard, D., Calabrese, D., Sirjusingh, C., Anderson, J. B., & Kohn, L. M. (2000) · Journal of Bacteriology · doi:10.1128/jb.182.6.1515-1522.2000 · Cited by 207
Biofilm formation in clinical Candida isolates and its association with virulence
Hasan, F., Xess, I., Wang, X., Jain, N., & Fries, B. C. (2009) · Microbes and Infection · doi:10.1016/j.micinf.2009.04.018 · Cited by 206
Global Analysis of the Evolution and Mechanism of Echinocandin Resistance in Candida glabrata
Singh-Babak, S. D., Babak, T., Diezmann, S., Hill, J. A., Xie, J. L., Chen, Y.-L., Poutanen, S. M., Rennie, R. P., Heitman, J., & Cowen, L. E. (2012) · PLoS Pathogens · doi:10.1371/journal.ppat.1002718 · Cited by 205 · cited 2×
“glabrata isolates recovered over a 10-month period from a patient that underwent caspofungin treatment for bloodstream candidemia [103].”
BackgroundKrogh-Madsen, M., Arendrup, M. C., Heslet, L., & Knudsen, J. D. (2006) · Clinical Infectious Diseases · doi:10.1086/500939 · Cited by 201
Cuéllar-Cruz, M., Briones-Martin-del-Campo, M., Cañas-Villamar, I., Montalvo-Arredondo, J., Riego-Ruiz, L., Castaño, I., & De Las Peñas, A. (2008) · Eukaryotic Cell · doi:10.1128/ec.00011-08 · Cited by 190
Kantarcioǧlu, A. S., & Yücel, A. (2002) · Mycoses · doi:10.1046/j.1439-0507.2002.00727.x · Cited by 170
Kaur, R., Castaño, I., & Cormack, B. P. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.5.1600-1613.2004 · Cited by 167 · cited 2×
“(azole-resistant) in response to azole exposure, probably through chromatin epigenetic modifications [51].”
BackgroundMartel, C. M., Parker, J. E., Bader, O., Weig, M., Gross, U., Warrilow, A. G. S., Kelly, D. E., & Kelly, S. L. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00303-10 · Cited by 165 · cited 1×
“It is thought that a decrease in the levels of ergosterol in the cell membrane is connected to the resistant phenotype [70, 71].”
BackgroundMolecular Mechanisms of Primary Resistance to Flucytosine in Candida albicans
Hope, W. W., Tabernero, L., Denning, D. W., & Anderson, M. J. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.11.4377-4386.2004 · Cited by 160
Katiyar, S. K., Alastruey-Izquierdo, A., Healey, K. R., Johnson, M. E., Perlin, D. S., & Edlind, T. D. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00813-12 · Cited by 148
Evolution in Candida albicans Populations During a Single Passage Through a Mouse Host
Forche, A., Magee, P. T., Selmecki, A., Berman, J., & May, G. (2009) · Genetics · doi:10.1534/genetics.109.103325 · Cited by 147 · cited 1×
“albicans in serial passage experiments through different host niches, namely kidney [121] and spleen [121, 122], two main target organs in murine Candida sepsis [123].”
BackgroundFerrari, S., Sanguinetti, M., De Bernardis, F., Torelli, R., Posteraro, B., Vandeputte, P., & Sanglard, D. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01271-10 · Cited by 144 · cited 1×
“glabrata clinical isolate not only exhibited mitochondrial dysfunction and upregulation of CDR1 and CDR2, but also was more virulent than its susceptible counterpart in both systemic and vaginal murine infection models [52].”
BackgroundHeilmann, C. J., Schneider, S., Barker, K. S., Rogers, P. D., & Morschhäuser, J. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01102-09 · Cited by 142
Candida spp. with Acquired Echinocandin Resistance, France, 2004–20101
Dannaoui, E., Desnos-Ollivier, M., Garcia-Hermoso, D., Grenouillet, F., Cassaing, S., Baixench, M.-T., Bretagne, S., Dromer, F., Lortholary, O., & the French Mycoses Study Group (2012) · Emerging infectious diseases · doi:10.3201/eid1801.110556 · Cited by 130
Candida albicans gains azole resistance by altering sphingolipid composition
Gao, J., Wang, H., Li, Z., Wong, A. H.-H., Wang, Y.-Z., Guo, Y., Lin, X., Zeng, G., Liu, H., Wang, Y., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06944-1 · Cited by 130 · cited 1×
“albicans can also gain azole resistance by altering sphingolipid composition, in vitro [40].”
BackgroundCandida glabrata displays pseudohyphal growth
Csank, C., & Haynes, K. (2000) · FEMS Microbiology Letters · doi:10.1111/j.1574-6968.2000.tb09216.x · Cited by 129
Roetzer, A., Gregori, C., Jennings, A. M., Quintin, J., Ferrandon, D., Butler, G., Kuchler, K., Ammerer, G., & Schüller, C. (2008) · Molecular Microbiology · doi:10.1111/j.1365-2958.2008.06301.x · Cited by 124
Vandeputte, P., Tronchin, G., Larcher, G., Ernoult, E., Bergès, T., Chabasse, D., & Bouchara, J.-P. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00423-08 · Cited by 117 · cited 1×
“It is thought that a decrease in the levels of ergosterol in the cell membrane is connected to the resistant phenotype [70, 71].”
BackgroundContribution of CgPDR1-Regulated Genes in Enhanced Virulence of Azole-Resistant Candida glabrata
Ferrari, S., Sanguinetti, M., Torelli, R., Posteraro, B., & Sanglard, D. (2011) · PLoS ONE · doi:10.1371/journal.pone.0017589 · Cited by 110 · cited 1×
“glabrata virulence [48], increased expression of adhesins and increased adherence to host epithelial cells [87, 102].”
BackgroundHoot, S. J., Smith, A. R., Brown, R. P., & White, T. C. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00995-10 · Cited by 107 · cited 3×
“albicans isolates had also described the occurrence of UPC2 GOF mutations that result in the overexpression of ERG11 and consequent azole resistance [31, 32].”
BackgroundRegulation of Candida glabrata oxidative stress resistance is adapted to host environment
Roetzer, A., Klopf, E., Gratz, N., Marcet-Houben, M., Hiller, E., Rupp, S., Gabaldón, T., Kovarik, P., & Schüller, C. (2011) · FEBS Letters · doi:10.1016/j.febslet.2010.12.006 · Cited by 90 · cited 1×
“however, Yap1 does not appear to be a virulence determinant and works in conjunction with other oxidative stress resistance (OSR) determinants to mediate phagocyte survival [137, 140].”
BackgroundBen-Ami, R., Zimmerman, O., Finn, T., Amit, S., Novikov, A., Wertheimer, N., Lurie-Weinberger, M., & Berman, J. (2016) · mBio · doi:10.1128/mbio.00655-16 · Cited by 88
Regulation of the CgPdr1 Transcription Factor from the Pathogen Candida glabrata
Paul, S., Schmidt, J. A., & Moye-Rowley, W. S. (2011) · Eukaryotic Cell · doi:10.1128/ec.00277-10 · Cited by 78 · cited 1×
“In fact, this phenotype is associated with Pdr1 expression, as mitochondrial dysfunction was shown to increase the expression of PDR1, further exacerbated by a positive auto-regulatory loop that leads to PDR1 and target genes overexpression [6, 50].”
BackgroundIn-vitro resistance to azoles associated with mitochondrial DNA deficiency in Candida glabrata
DEFONTAINE, A., BOUCHARA, J.-P., DECLERK, P., PLANCHENAULT, C., CHABASSE, D., & HALLET, J.-N. (1999) · Journal of Medical Microbiology · doi:10.1099/00222615-48-7-663 · Cited by 65 · cited 1×
“glabrata populations has been linked to a loss of mitochondrial function, which leads to the upregulation of ABC transporter genes [47, 49].”
BackgroundComparative Genomics of Two Sequential Candida glabrata Clinical Isolates
Vale-Silva, L., Beaudoing, E., Tran, V. D. T., & Sanglard, D. (2017) · G3 Genes|Genomes|Genetics · doi:10.1534/g3.117.042887 · Cited by 61 · cited 2×
“glabrata resistant isolates was demonstrated in vivo by others [86, 87], but their role in drug resistance was never analyzed until this study that enhances the presence of yet unknown mechanisms driving acquisition of resistance.”
BackgroundCompetitive Fitness of Fluconazole-Resistant Clinical Candida albicans Strains
Popp, C., Hampe, I. A. I., Hertlein, T., Ohlsen, K., Rogers, P. D., & Morschhäuser, J. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00584-17 · Cited by 56
Molecular Mechanisms of Resistance to 5-Fluorocytosine in Laboratory Mutants of Candida glabrata
Vandeputte, P., Pineau, L., Larcher, G., Noel, T., Brèthes, D., Chabasse, D., & Bouchara, J.-P. (2011) · Mycopathologia · doi:10.1007/s11046-010-9342-1 · Cited by 55
Candidemia surveillance in Iowa: emergence of echinocandin resistance
Matsumoto, E., Boyken, L., Tendolkar, S., McDanel, J., Castanheira, M., Pfaller, M., & Diekema, D. (2014) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2014.02.016 · Cited by 50
Khatib, R., Johnson, L. B., Fakih, M. G., Riederer, K., & Briski, L. (2016) · Mycoses · doi:10.1111/myc.12531 · Cited by 48
Costa, C., Ponte, A., Pais, P., Santos, R., Cavalheiro, M., Yaguchi, T., Chibana, H., & Teixeira, M. C. (2015) · PLOS ONE · doi:10.1371/journal.pone.0135110 · Cited by 46
Self-citationNovel point mutations in the ERG11 gene in clinical isolates of azole resistant Candida species
Silva, D. B. D. S., Rodrigues, L. M. C., Almeida, A. A. D., Oliveira, K. M. P. D., & Grisolia/, A. B. (2016) · Memórias do Instituto Oswaldo Cruz · doi:10.1590/0074-02760150400 · Cited by 42
Fukuda, Y., Tsai, H.-F., Myers, T. G., & Bennett, J. E. (2013) · Infection and Immunity · doi:10.1128/iai.00851-12 · Cited by 41
Biswas, C., Chen, S. C.-A., Halliday, C., Kennedy, K., Playford, E. G., Marriott, D. J., Slavin, M. A., Sorrell, T. C., & Sintchenko, V. (2017) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2017.03.014 · Cited by 36 · cited 1×
“glabrata antifungal resistance markers to simultaneously unveil mutation patterns of genes known to be involved in resistance toward different drug classes [106].”
BackgroundEvolutionary Dynamics of Candida albicans during In Vitro Evolution
Huang, M., McClellan, M., Berman, J., & Kao, K. C. (2011) · Eukaryotic Cell · doi:10.1128/ec.05168-11 · Cited by 34 · cited 2×
“Due to the limited number of clones isolated, the population dynamics during the emergence of drug resistance in vivo has been difficult to assess [89].”
BackgroundSalazar, S. B., Wang, C., Münsterkötter, M., Okamoto, M., Takahashi-Nakaguchi, A., Chibana, H., Lopes, M. M., Güldener, U., Butler, G., & Mira, N. P. (2018) · FEMS Yeast Research · doi:10.1093/femsyr/fox079 · Cited by 31 · cited 1×
“sistance toward fluconazole and voriconazole [53].”
Cited by
Fungal infections in humans: the silent crisis
Kainz, K., Bauer, M. A., Madeo, F., & Carmona-Gutierrez, D. (2020) · Microbial Cell · doi:10.15698/mic2020.06.718 · Cited by 369
Carolus, H., Pierson, S., Muñoz, J. F., Subotić, A., Cruz, R. B., Cuomo, C. A., & Van Dijck, P. (2021) · mBio · doi:10.1128/mbio.03333-20 · Cited by 211
“This and other studies in bacteria (66) and fungi (13, 65, 67) show 382 that in vitro experimental evolution can be a powerful tool, especially if combined with an 383 effective approach to trace the full evolutionary history of mutation events, as we did here 384 using allele-specific PCR screening 385 386 Candida au…”
BackgroundMethodRecent advances in understanding Candida albicans hyphal growth
Arkowitz, R. A., & Bassilana, M. (2019) · F1000Research · doi:10.12688/f1000research.18546.1 · Cited by 51
Mba, I. E., Nweze, E. I., Eze, E. A., & Anyaegbunam, Z. K. G. (2022) · Infection, Genetics and Evolution · doi:10.1016/j.meegid.2022.105256 · Cited by 46
Lin, C.-J., Yang, S.-Y., Hsu, L.-H., Yu, S.-J., & Chen, Y.-L. (2023) · Medical Mycology · doi:10.1093/mmy/myad004 · Cited by 7
Metadata
- Authors
- Pais, P., Galocha, M., Viana, R., Cavalheiro, M., Pereira, D., & Teixeira, M. C.
- Venue
- Microbial Cell
- Publisher
- Shared Science Publishers OG
- Published
- 2019-03-04
- Volume
- 6
- Issue
- 3
- Pages
- 142-159
- ISSN
- 2311-2638 (ISSN-L)
- OpenAlex
- W2917390930
- Cited by
- 51
- References
- 85
- FWCI
- 5.15
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.